Aurion Biotech Announces Members of Medical Advisory Board

Aurion Biotech Announces Members of Medical Advisory Board

October 19, 2021

Aurion Biotech has revealed its medical advisory board, which includes some of the world's most renowned ophthalmologists.

The board, which is chaired by Edward Holland, MD, who was recently hired as Aurion Biotech's top medical adviser, will engage with the company's management team in clinical development.

“The doctors on this board are among the best in our field,” said Dr. Holland.

“Their expertise, commitment to, and enthusiasm for Aurion Biotech’s cell therapy speak volumes about the transformational potential of this treatment to cure blindness resulting from corneal endothelial disease. I welcome their contributions. It’s a privilege to work closely with each of them.”

The company’s first candidate in development is a cell therapy for the treatment of corneal endothelial dysfunction.

It was invented by leading ophthalmic surgeon and research scientist Professor Shigeru Kinoshita and his distinguished colleagues at Kyoto Prefecture University of Medicine (KPUM) in Japan.

I’ve had the good fortune to catalyze innovations in ophthalmology for many years, and I’m confident that Aurion Biotech has all the key ingredients for success,” said Richard Lindstrom, MD, Aurion Biotech board member and medical advisor, and founder and attending surgeon of Minnesota Eye Consultants.

In addition to Dr. Holland and Dr. Lindstrom, the following physicians have been named to Aurion Biotech’s medical advisory board:

“We are extremely fortunate, not only because our medical advisors are some of the most talented corneal specialists in ophthalmology, but they are also deeply involved in the work we are doing,” said Greg Kunst, chief executive officer of Aurion Biotech.